HER2-targeted Therapy: Routes of Administration

Evaluating the benefits of the subQ vs IV formulation of the trastuzumab-pertuzumab combination for the management of HER2+ breast cancer and examining the potential use of at-home administration.

Evaluating the benefits of the subQ vs IV formulation of the trastuzumab-pertuzumab combination for the management of HER2+ breast cancer and examining the potential use of at-home administration.

Related Content:

VideosBreast Cancer
The Food-Mood Connection: Diet Directly Impacts Emotional Health
Chemotherapy Available at Home with Launch of CTCA Program
FDA Approves Pembrolizumab for High-Risk Early-Stage TNBC